Loading…
Company enters into exclusive distribution agreement with Calmino group AB.
Immuron Limited (Nasdaq: IMRN) announced on September 4, 2026, the launch of its product PROIBS® in the United States. This launch is facilitated through an exclusive distribution agreement with Calmino group AB.
The agreement involves a market with an estimated value of $4.16 billion. Immuron reported that PROIBS® has shown efficacy rates of 94%, 91%, and 98% in various user studies, with a current user base of 1,003 individuals.
As of the latest data, Immuron has a free float of 6,769,739 shares.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.